Drug Discovery · Cambridge, United Kingdom · Founded 2015 · Privately Held (backing)
Developer of novel cancer treatments designed to target the deoxyribonucleic acid (DNA) damage response. Artios is based in Cambridge, United Kingdom and was founded in 2015. It was valued at $260 million at its later-stage round in Nov 2025, the last priced event on record. It has raised $385 million across 1 recorded round; the latest was an $114 million Series D in Nov 2025.
PMV mark · valuation
$260.3M
Oct 2026
Priced at
its later-stage round
Nov 2025
Total raised
$384.5M
Last round
Later Stage VC (Series D)
Nov 2025
No prints on record
No secondary trades in Artios shares have been recorded yet. When market activity lands it appears here as monthly aggregates and, for platform-recorded trades, dated prints.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Artios with a free account
·The complete investor list: 27 names
·Watch Artios: the Monday email on marks, rounds and moves
Secondary marks are indicative month-end price levels observed across secondary-market trading venues — a level, not a trade — and are the market input to the PrivateMarketView mark. Private share prices aren’t published anywhere. Aggregate figures combine multiple reporting channels — direct participant reports, platform transactions, third-party market intelligence — at monthly granularity. Individually dated prints are a Pro feature and are shown only for transactions recorded on our own platform. Third-party-reported trades are never republished individually, at any tier. Verified prints (✓) have been confirmed against a second source. Prints marked SPV or Forward reflect the structure’s pricing, which can differ from direct share transfers of Artios stock.
